SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Mumtaz Mahal

PatientMumtaz Mahal
Date of birth1988-04-27
IdentifiersMRN HR-RE006-SYN; SSN (made up) 000-06-7184
Document date2026-03-03
AuthorFarzana Qureshi-Lindholm, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Prenatal visit at 21 weeks with the anatomy scan. [S]

History of Present Illness

Mumtaz Mahal returns at 21 weeks 2 days, four weeks after her first intravenous iron dose, which she tolerated without reaction. She has more energy and is less breathless. It is the month of Ramadan; she has chosen not to fast during the pregnancy, as her faith allows, and plans to make up the days later. She feels the baby move every day. She takes aspirin and folic acid. She has no headache, visual change, abdominal pain, contractions, bleeding, or urinary symptoms. She had the anatomy scan this morning. [S]

ElementDetail
IronFirst intravenous dose four weeks ago, no reaction; more energy
FastingNot fasting this Ramadan, by her own choice
Fetal movementDaily
ScanAnatomy scan this morning

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy better
CardiovascularNegativeBreathless only on several flights of stairs
GastrointestinalNegativeNausea and constipation gone since stopping oral iron
GenitourinaryNegativeNo bleeding, leaking fluid, or urinary symptoms

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-06activeS
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other dayOne tablet every other morning with water or orange juice, apart from tea and calciumOral route2026-01-06 to 2026-02-03completedS
Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtimeOne tablet by mouth at bedtime until deliveryOral route2026-01-06activeS
Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses)Single infusion; two doses in total, four weeks apartIntravenous route2026-02-03 to 2026-02-03completedS
Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses)Single infusion; two doses in total, four weeks apartIntravenous route2026-03-03 to 2026-03-03completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-03Body height157cmS
2026-03-03Body weight61.9kgS
2026-03-03Body mass index (BMI) [Ratio]25.1kg/m2S
2026-03-03Systolic blood pressure104mm[Hg]S
2026-03-03Diastolic blood pressure62mm[Hg]S
2026-03-03Heart rate88/minS
2026-03-03Respiratory rate14/minS
2026-03-03Body temperature36.7CelS
2026-03-03Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-03Hemoglobin [Mass/volume] in Blood10.9g/dL10.5-15 g/dLNormalS
2026-03-03Ferritin [Mass/volume] in Serum or Plasma96ng/mL30-150 ng/mLNormalS
2026-03-03Fetal Body weight estimated by US410gAbout the 50th centile for 21 weeksNormalS

Physical Exam

Vital signs recorded on 2026-03-03; see the Vital Signs section. [S]

SystemFinding
GeneralWell; better color
AbdomenFundal height 21 cm; non-tender
FetalScan: normal anatomy, estimated weight 410 g; fetal heart 148 per minute
PlacentaPosterior and fundal, lower edge more than 5 cm from the internal os; no lacunae; normal retroplacental clear zone
Urine dipstickProtein negative

Problems

ProblemClinical statusVerificationCodeProvenance
Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12activeconfirmed O09.529S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic.
Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living childrenactiveconfirmed O09.40S — Synthetic modern problem anchored to her documented thirteen earlier births.
Short interpregnancy interval: conception about five and a half months after her last birthactiveconfirmed O09.899S — Synthetic modern problem anchored to the documented fourteen months between her last two births.
Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mLactiveconfirmed O99.019S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure and urine proteinEvery prenatal visitCompleted today104/62 mmHg; urine protein negative
ExaminationFetal heart and fundal heightEvery prenatal visitCompleted todayFetal heart 148 per minute; fundal height 21 cm
ExaminationWeight gainEvery prenatal visitCompleted today61.9 kg, up 3.3 kg since intake
LaboratoryHemoglobin and ferritinAt intake, four weeks after starting treatment, at 24 to 28 weeks, and before deliveryCompleted todayHemoglobin 10.9 g/dL and ferritin 96 ng/mL after the first intravenous dose; second dose today
Medication safetyIntravenous iron infusion safetyWith each infusionCompleted todayNo reaction to the first dose; second dose given with 30 minutes of observation, no reaction
ImagingDetailed anatomy scan with placental locationAt 18 to 22 weeksCompleted todayNormal anatomy; estimated weight 410 g; placenta posterior fundal, clear of the os; no signs of accreta
ImagingRepeat placental scan at 32 weeksOnly if the placenta is low-lying or covers the osNot indicatedPlacenta well clear of the os
Medication safetyLow-dose aspirinDaily from 12 to 16 weeks until delivery; review at every visitCompleted todayTaken nightly; no bruising or bleeding
LaboratoryGestational diabetes screenAt 24 to 28 weeksDueGlucose challenge booked for 27 weeks
SurveyPerinatal mood screen (EPDS)Each trimesterDueSecond-trimester screen at 27 weeks
Self-managementPostpartum hemorrhage risk assessment and birth planAt intake, in the third trimester, and on admission for birthUp to dateNo placenta previa or accreta; risk factors remain grand multiparity and anemia, now improving

Goal progress:

Guideline basis: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021); Obstetric Care Consensus No. 7: Placenta Accreta Spectrum (2018)

Follow-up: Prenatal visit at 27 weeks with the glucose challenge, blood count, and Tdap. Next scheduled visit 2026-04-14: prenatal visit at 27 weeks: glucose challenge, blood count, and Tdap. [S]